NEOG

Over the past six months, Neogen's stock price increased by 145.44% from September 29, 2025, to September 28, 2026, and saw a significant gain of +22.7% on July 30, 2026, after earnings, and surged 9.8% on October 7, 2026, in pre-market trading. However, shares fell over 7% on October 7, 2026, following an FDA warning regarding the recalled Neogen Vet product HYCOAT, which was voluntarily recalled on January 28, 2026, due to microbial contamination linked to serious infections and at least 20 horse deaths. Other events include Neogen's agreement to sell its Genomics business to Zoetis for $160 million, pending regulatory approval, and the company reported its first-quarter fiscal year 2027 financial results on October 6, 2026, with revenue rising 6.5% and core growth of 8.1%, leading to raised full-year guidance and a growth strategy outlined at its 2026 Investor Day.